Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
YBX3 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
GEO DataSets Gene Profile neighbors Chromosome neighbors Homologene neighbors
LRP1 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
EMILIN2 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
PLXDC2 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
RNF130 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
SPI1 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
PKM - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
LGALS3 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
APLP2 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
IGSF6 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
NELFCD - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
RRAGD - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
P2RX1 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
CTSH - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
NCOA1 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
ANXA5 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
COTL1 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
ERCC2 - IFNβ-1a in vivo treatment effect on CIS multiple sclerosis patients: peripheral blood mononuclear cells
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on